Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients.
A stable and sustained suppression of growth hormone (GH) secretion was noted in 101 patients treated long term with individual doses (20 and 30 mg in 89 patients, 40 mg in 12 patients) of Sandostatin LAR (Sandoz Pharma Ltd, Basel, Switzerland). Doses of 20 mg and 30 mg at 4-week intervals delivered average octreotide concentrations of 1,348 +/- 483 ng/L and 2,631 +/- 1,026 ng/L, respectively, in steady-state conditions and provided adequate control of patients who had been well controlled during treatment with 0.1 mg and 0.2 mg thrice-daily subcutaneous (SC) Sandostatin. Suppression of GH serum concentrations to less than 5 micrograms, 2 micrograms, and even 1 microgram/L was recorded in more patients and more consistently during long-term treatment with Sandostatin LAR than Sandostatin. A marked decrease or even a normalization of insulin-like growth factor-1 (IGF-1) serum concentrations was observed after the first double-blind 10-, 20-, or 30-mg dose of Sandostatin LAR. A progressive improvement was recorded during long-term treatment, with normalization of IGF-1 serum concentrations in 65.3% of patients. A marked clinical improvement was observed in parallel, with 36 of 101 patients (35.6%) becoming asymptomatic after the nineteenth injection of Sandostatin LAR. A greater than 20% shrinkage of the GH-secreting adenoma was also recorded in 12 of 14 patients treated with Sandostatin LAR after receiving only 2 to 4 weeks of treatment with SC Sandostatin and in 11 of 18 patients receiving Sandostatin LAR as adjuvant therapy after failure of surgery. The systemic tolerability of Sandostatin LAR was good, and most adverse events were mild and short term (1 to 2 days). No impairment of thyroid function was detected. Newly occurring gallstones were recorded in four of 101 patients and microlithiasis in four of 101 after up to 30 months of treatment with Sandostatin LAR. Due to its excellent efficacy, good tolerability, convenience of administration, and acceptability by patients, Sandostatin LAR is considered a promising therapeutic tool in the management of acromegalic patients.
Lancranjan
I
I
Department of Oncology, Sandoz Pharma Ltd, Basel, Switzerland.
Bruns
C
C
Grass
P
P
Jaquet
P
P
Jervell
J
J
Kendall-Taylor
P
P
Lamberts
S W
SW
Marbach
P
P
Orskov
H
H
Pagani
G
G
Sheppard
M
M
Simionescu
L
L
D000172:Acromegaly / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D000236:Adenoma / Q000473:pathology; D002214:Capsules; D004311:Double-Blind Method; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008863:Microspheres; D015282:Octreotide / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D010911:Pituitary Neoplasms / Q000473:pathology; D011446:Prospective Studies
D002214:Capsules; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D015282:Octreotide